

Cancer Drug Resistance

[CDR, ISSN 2578-532X (Online)]

is a gold open access international journal founded in 2018 by OAE Publishing Inc. Journal Homepage



Twitter

LinkedIn

WeChat Account

Editor-in-Chief: Godefridus J. (Frits) Peters, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers (Amsterdam UMC), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland.

Editorial Board: 54 scientists from 11 countries or regions

Aims and Scope: The journal publishes research articles, reviews, commentaries, perspectives, and letters on pharmacological aspects of drug resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance.


Indexing: ESCI, PubMed Central (PMC), Scopus, CAS, CNKI, Dimensions, Lens, Embase

Journal Metric and Ranking: **Impact Factor (IF): 4.6, JCR Q1 (ONCOLOGY);**

Next IF > 5.2

CiteScore: 6.6, Q1 [Pharmacology (medical)]

Spotlight on cutting-edge pharmacological findings on cancer drug resistance and its reversal



Genomic and Genetic Alterations Associated with Cancer Drug Resistance

Dr. Christophe P. Nicot
University of Kansas Medical
Center, Kansas, KS, USA.




Advancements in Precision Medicine for Overcoming Cancer Drug Resistance

Prof. Juyoung Yoon
Ewha Womans University, Seoul, South Korea.
Prof. Jianliang Shen
Wenzhou Medical University, Zhejiang, China.



Overcoming Drug Resistance in Solid Tumors: Nanotechnology, Precision Medicine, and Multimodal Therapies

Prof. Bingya Liu & Dr. Xi Cheng
Ruijin Hospital, Shanghai Jiaotong
University School of Medicine,
Shanghai, China.



Dr. Michael M. Gottesman, Dr. Robert W. Robey, and
Dr. Suresh V. Ambudkar
Laboratory of Cell Biology, Center for Cancer Research,
National Cancer Institute, National Institutes of Health,
Bethesda, MD, USA.

OAE
Open Access with Excellence

CDR
Cancer Drug Resistance

Contact us:

Managing Editor: Louise Pan, Louise@cdrjournal.com

Editorial Office: editorial@cdrjournal.com

Journal Homepage: <https://www.oaepublish.com/cdr>

Editorial Board

Editor-in-Chief



Godefridus J. (Frits) Peters

Amsterdam University Medical Centers (Amsterdam UMC), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Associate Editors



Wafik S. El-Deiry

Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Brown University, Providence, RI, USA.



Elisa Giovannetti

Cancer Center Amsterdam, Amsterdam University Medical Centers (Amsterdam UMC), Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Pharmacology Lab, Fondazione Pisana per la Scienza, Pisa, Italy.



Paola Perego

Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.



Chiara Riganti

Department of Oncology, University of Torino, Torino, Italy.



Liwu Fu

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.



Hailin Tang

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Publication Information

1. Global Reach, Maximum Impact

● **Gold Open Access:** Immediate, free access upon publication with no barriers to dissemination.

● **Instant Visibility:** Indexed in PubMed, Web of Science, and Scopus upon publication.

2. **Publication Timeline:** Average 100 days from submission to online publication; accepted articles go live in 3 days.

3. **Article Processing Charge (APC):** \$2800 per article.

Featured Articles

NFE2L2 and ferroptosis resistance in cancer therapy

Correspondence to: Dr. Daolin Tang, Dr. Rui Kang, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TA, USA.



Circular RNA circNCOA3 promotes tumor progression and anti-PD-1 resistance in colorectal cancer

Correspondence to: Prof. Dong-Liang Chen, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.



The evolving role of immune checkpoint inhibitors in cervical and endometrial cancer

Correspondence to: Dr. Ilaria Colombo, Medical Oncology, Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland.



Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment

Correspondence to: Prof. Marina Konopleva, Department of Medicine (Oncology) and Molecular Pharmacology, Albert Einstein College of Medicine and Montefiore Medical Center, USA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, USA.



Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects

Correspondence to: Prof. William H. Gmeiner, Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest University School of Medicine, USA.



Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma

Correspondence to: Dr. Fabio Calabrò, Medical Oncology, San Camillo Forlanini Hospital, Italy; Medical Oncology, IRCCS, National Cancer Institute Regina Elena, Italy.

